Risk factors for high level cytomegalovirus viremia in liver transplant recipients and associated outcomes-Reference-Cited by-同舟云学术

Risk factors for high level cytomegalovirus viremia in liver transplant recipients and associated outcomes

Published:2022-07-13 Issue:4 Volume:24 Page:
ISSN:1398-2273
Container-title:Transplant Infectious Disease
language:en
Short-container-title:Transplant Infectious Dis

Author:

Kleiboeker Hanna L.¹,Jorgenson Margaret R.¹^ORCID,Leverson Glen E.²,Rice John P.³,Saddler Christopher M.³^ORCID,Smith Jeannina A.³^ORCID,Al‐Adra David²

Affiliation:

1. Department of Pharmacy University of Wisconsin Hospital and Clinics Madison Wisconsin USA

2. Department of Surgery, University of Wisconsin‐Madison School of Medicine and Public Health University of Wisconsin Hospital and Clinics Madison Wisconsin USA

3. Department of Medicine, University of Wisconsin‐Madison School of Medicine and Public Health University of Wisconsin Hospital and Clinics Madison Wisconsin USA

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tid.13898

Reference27 articles.

1. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

2. Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients

3. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation

4. The Association of Cytomegalovirus Sero-Pairing with Outcomes and Costs Following Cadaveric Renal Transplantation Prior to the Introduction of Oral Ganciclovir CMV Prophylaxis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of cytomegalovirus infection after liver transplantation;World Journal of Transplantation;2024-09-18

2. Cytomegalovirus Post‐Prophylaxis Surveillance in High‐Risk Kidney and Liver Recipients Prevents CMV End‐Organ Disease and Ganciclovir‐Resistance;Clinical Transplantation;2024-09

3. The next frontier: cytomegalovirus antiviral stewardship programs in solid organ transplant;Current Opinion in Infectious Diseases;2023-10-10

4. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction;Clinical Transplantation;2023-09-27